LivaNova PLC
NASDAQ:LIVN
Intrinsic Value
LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. [ Read More ]
The intrinsic value of one
LIVN
stock under the Base Case scenario is
81.29
USD.
Compared to the current market price of 52.88 USD,
LivaNova PLC
is
Undervalued by 35%.
Whether you're assessing long-term stability or short-term opportunities, Historical Valuation serves as a vital tool to enhance your investment approach, enabling you to make more informed investment decisions.
Sign up
to access LivaNova PLC's intrinsic value history.
No restrictions, no limits.
All stocks, all tools.
Look for stocks that have been historically overvalued but are now trading below their intrinsic value.
Avoid stocks that are always undervalued and never reach their intrinsic value.
Find stocks that have historically corrected quickly from being undervalued to reaching their intrinsic value.
There are two methods to calculate the Intrinsic Value of a stock: DCF Valuation and Relative Valuation. We take the average of these two methods to estimate the intrinsic value as accurately as possible. You can see the Intrinsic Value of a stock at the top of this page.
DCF Value
Discounted Cash Flow
Fundamental Analysis
Balance Sheet Decomposition
LivaNova PLC
| Current Assets | 942m |
| Cash & Short-Term Investments | 223m |
| Receivables | 186m |
| Other Current Assets | 533m |
| Non-Current Assets | 1.4B |
| Long-Term Investments | 21.7m |
| PP&E | 184m |
| Intangibles | 1.1B |
| Other Non-Current Assets | 57.6m |
| Current Liabilities | 288m |
| Accounts Payable | 78.2m |
| Accrued Liabilities | 127m |
| Other Current Liabilities | 82.9m |
| Non-Current Liabilities | 813m |
| Long-Term Debt | 568m |
| Other Non-Current Liabilities | 245m |
LIVN Profitability Score
Profitability Due Diligence
LivaNova PLC's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
Score
LivaNova PLC's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
LIVN Solvency Score
Solvency Due Diligence
LivaNova PLC's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Score
LivaNova PLC's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LIVN Price Targets Summary
LivaNova PLC
According to Wall Street analysts, the average 1-year price target for
LIVN
is 68.21 USD
with a low forecast of 57.57 USD and a high forecast of 86.1 USD.
Ownership
LIVN Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
LIVN Price
LivaNova PLC
| Average Annual Return | -5.79% |
| Standard Deviation of Annual Returns | 27.58% |
| Max Drawdown | -73% |
| Market Capitalization | 2.8B USD |
| Shares Outstanding | 53 768 100 |
| Percentage of Shares Shorted | 4.27% |
Company Profile
LivaNova PLC
Country
Industry
Market Cap
Dividend Yield
Description
LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. The firm is focused on the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems throughout the world. The firm operates through two segments: Cardiac Surgery and Neuromodulation. Its Cardiac Surgery Business Franchise (CS) is engaged in the development, production and sale of cardiac surgery products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and other accessories used for extracorporeal circulation, systems for autologous blood transfusion and blood washing. Its Neuromodulation Business Franchise designs develops and markets neuromodulation-based medical devices for the treatment of epilepsy and difficult-to-treat depression (DTD) and obstructive sleep apnea.
Contact
IPO
Employees
Officers
The intrinsic value of one
LIVN
stock under the Base Case scenario is
81.29
USD.
Compared to the current market price of 52.88 USD,
LivaNova PLC
is
Undervalued by 35%.
Sensibly Priced Quality
Significantly Undervalued
Magic Formula
High Growth
